Organization (Industry)
Cytori Therapeutics (United States)
ClinicalTrials.gov lists Cytori Therapeutics (United States) as lead sponsor of 19 trials. It has 11 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Cytori Therapeutics (United States): 19 lead-sponsored trials and 1 legal-entity registration.
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Artery Disease | 5 |
| Coronary Disease | 5 |
| Glioma | 3 |
| Scleroderma, Systemic | 3 |
| Brain Neoplasms | 2 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 5 |
| 2014 | 5 |
| 2013 | 1 |
| 2012 | 2 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (11)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 186RNL | Meningeal Carcinomatosis | Phase 1/2 | 2 |
| 186RNL | Neoplasm Metastasis | Phase 1/2 | 1 |
| Rhenium Liposome Treatment | Brain Neoplasms | Phase 1/2 | 1 |
| Rhenium Liposome Treatment | Glioblastoma | Phase 1/2 | 1 |
| Rhenium Liposome Treatment | Glioma | Phase 1/2 | 1 |
Showing 5 of 11 active programs.
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American heart journal | 1 |
| Arthritis & rheumatology (Hoboken, N.J.) | 1 |
| Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions | 1 |
| Computers in biology and medicine | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 45 | 0 | 2018-11-06 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 5,213,000 | -22,386,000 | 8,379,000 |
| 2024 | 5,824,000 | -12,978,000 | 10,580,000 |
| 2023 | 4,913,000 | -13,316,000 | 9,690,000 |
| 2022 | not reported | -20,275,000 | 9,698,000 |
| 2021 | not reported | -13,399,000 | 5,323,000 |
| 2020 | not reported | -8,241,000 | 2,700,000 |
| 2019 | not reported | -10,887,000 | 5,365,000 |
| 2018 | 3,671,000 | -12,634,000 | 5,523,000 |
| 2017 | 2,689,000 | -22,686,000 | 11,678,000 |
| 2016 | 4,656,000 | -22,046,000 | 16,197,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (68)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-01 | ATM offering | not disclosed | Sec extracted |
| 2026-01-15 | Public offering | 13,300,000 | Sec extracted |
| 2026-01-14 | Other financing | not disclosed | Edgar offerings |
| 2025-08-15 | Other financing | not disclosed | Edgar offerings |
| 2025-08-07 | ATM offering | 2,000,000 | Sec extracted |
Showing 5 of 68 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Peking University People's Hospital | Co sponsors trial with | 1 |
| Lurie Children's Hospital | Co sponsors trial with | 1 |
| Huashan Hospital | Co sponsors trial with | 1 |
| Nanfang Hospital, Southern Medical University | Co sponsors trial with | 1 |
Latest dated events (138)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-15 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-14 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 138 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AMH | Trial sponsor | Named in trial inclusion criteria |
| F3 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Exploratory endpoint in a trial |
| F2 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 16 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sponsor delivery record, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.